By Brian Mahoney ( July 15, 2013, 6:03 PM EDT) -- Pfizer Inc.'s rheumatoid arthritis drug Xeljanz has received approval for use in five more countries, including Switzerland, the company said Monday, adding that it hoped a European Union health board would soon reverse a negative review of the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.